IsoRay

IsoRay Change in Working Capital

Delisted

The Change in Working Capital of IsoRay (ISR) as of Nov 4, 2026 is -1.85 M USD. In the previous year, Change in Working Capital was -67,000.00 USD — a change of 2,661.19% (lower).

Change in Working Capital

-1.85 MUSD

YoY

2,661.19%

Last updated:

Change in Working Capital of IsoRay is 2022 -1.85 M USD. Change in Working Capital of IsoRay was 2021 -67,000.00 USD. It decreases by 2,661.19% lower compared to the previous year.

The IsoRay Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2015
-357,515.00 USD
Jan 1, 2016
401,265.00 USD
Jan 1, 2017
17,000.00 USD
Jan 1, 2018
222,000.00 USD
Jan 1, 2019
-518,000.00 USD
Jan 1, 2020
-835,000.00 USD
Jan 1, 2021
-67,000.00 USD
Jan 1, 2022
-1.85 M USD
The IsoRay Change in Working Capital history
YEARChange in Working CapitalYoY
-1.85 MUSD+2,661.19%
-67,000.00USD-91.98%
-835,000.00USD+61.20%
-518,000.00USD-333.33%
222,000.00USD+1,205.88%
17,000.00USD-95.76%
401,265.00USD-212.24%
-357,515.00USD-192.41%
386,869.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IsoRay Stock analysis

What does IsoRay do? The company IsoRay Inc is a leading global company in the field of brachytherapy and specializes in the development of novel medical devices for the treatment of cancer. The company's history dates back to the 1980s when it was founded by a team of doctors and scientists. IsoRay Inc's business model is based on the research, development, and manufacturing of medical products used in the treatment of cancer. Brachytherapy is a particularly important focus. This involves a treatment method where radioactive seeds or sources are directly implanted into the tumor. The radiation destroys the cancer cells without damaging the surrounding tissue. IsoRay Inc's product range includes a variety of medical devices and accessories for conducting brachytherapy procedures. The company specializes in the development of high-tech products that enable precise and effective radiation therapy. This includes, for example, radioactive seeds that are directly implanted into the tumor or apparatuses that can selectively use radiation in specific structures of the body. A special focus of IsoRay Inc is computer-assisted planning of brachytherapy treatments. The tumor is precisely measured and the radiation sources are individually customized based on the data to achieve an optimal radiation dose. This planning is done using modern software and is an important factor for the successful treatment of cancer. In addition to research and development of medical products, IsoRay Inc also encompasses the production and distribution of these products. The company operates in more than 30 countries worldwide and collaborates closely with numerous clinics and practices to research and improve new technologies in the field of radiation therapy. One of IsoRay Inc's most well-known products is the "Cesium-131 Brachytherapy seed." This radioactive seed is particularly small and therefore ideal for targeted radiation therapy of tumors. It is used in almost all clinical areas worldwide and is considered particularly safe and effective. Other products of the company include the "Gladius™ Applicator Needle," a device for precise placement of radiation sources in tumors, as well as "Intraoperative Application Systems" that enable effective radiation therapy during surgery. Overall, IsoRay Inc is considered an innovative and successful company in the field of brachytherapy and radiation therapy. The constant development and improvement of its own products is a key factor for the company's success. High quality and close collaboration with research and practice are central to its operations. IsoRay is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IsoRay stock

Change in Working Capital of IsoRay is -1.85 M USD in 2022.

Change in Working Capital of IsoRay changed from -67,000.00 USD to -1.85 M USD, representing a 2,661.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital IsoRay since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's IsoRay historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — IsoRay

All Key Metrics — IsoRay